Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.69 |
| ▸ | ATM | Q13315 | 2/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | PLG | P00747 | 1/20 | 0.44 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.44 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.44 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.44 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.43 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.43 |
| ▸ | ACE | P12821 | 1/20 | 0.43 |
| ▸ | ACACB | O00763 | 1/20 | 0.43 |
| ▸ | ACACA | Q13085 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16609114 | 1.00 | KMT2A (0.69) | KMT2AATMMEN1MAPK1LMNA | |
| SCHEMBL17982930 | 0.91 | KMT2A (0.58) | KMT2AATMMEN1MAPK1PLG | |
| SCHEMBL16604420 | 0.91 | KMT2A (0.58) | KMT2AATMMEN1MAPK1PLG | |
| SCHEMBL28057010 | 0.91 | KMT2A (0.58) | KMT2AATMMEN1MAPK1PLG | |
| SCHEMBL16604417 | 0.91 | KMT2A (0.70) | KMT2AATMMEN1MAPK1LMNA | |
| SCHEMBL25964562 | 0.91 | KMT2A (0.70) | KMT2AATMMEN1MAPK1LMNA | |
| SCHEMBL388984 | 0.91 | KMT2A (0.82) | KMT2AATMMEN1MAPK1LMNA | |
| SCHEMBL388983 | 0.91 | KMT2A (0.82) | KMT2AATMMEN1MAPK1LMNA | |
| SCHEMBL28057007 | 0.91 | KMT2A (0.82) | KMT2AATMMEN1MAPK1LMNA | |
| SCHEMBL16604445 | 0.90 | KMT2A (0.69) | KMT2AATMMEN1MAPK1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230201383-A1 | PSMA TARGETING UREA-BASED LIGANDS FOR PROSTATE CANCER RADIOTHERAPY AND IMAGING | RIGSHOSPITALET (DK) | 2023-06-29 | — | — | US | disclosed |
| US-20160280699-A1 | SUBSTITUTED PHENYLALANINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-09-29 | — | — | US | disclosed |
| US-20160272617-A1 | SUBSTITUTED PHENYLALANINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-09-22 | — | — | US | disclosed |
| US-20160237044-A1 | SUBSTITUTED PHENYLALANINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-08-18 | — | — | US | disclosed |
| US-20160237067-A1 | SUBSTITUTED PHENYLALANINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230201383-A1 | PSMA TARGETING UREA-BASED LIGANDS FOR PROSTATE CANCER RADIOTHERAPY AND IMAGING | KLK3, FOLH1, PSMA7 | KMT2A 2730/4885ATM 114/4885MEN1 865/4885 |
| US-20160272617-A1 | SUBSTITUTED PHENYLALANINE DERIVATIVES | PAH, PEPD, AADAT | KMT2A 1451/4885ATM 1339/4885MEN1 1857/4885 |
| US-20160237044-A1 | SUBSTITUTED PHENYLALANINE DERIVATIVES | PAH, AADAT, TTR | KMT2A 1317/4885ATM 1478/4885MEN1 2609/4885 |
| US-20160280699-A1 | SUBSTITUTED PHENYLALANINE DERIVATIVES | PAH, PEPD, AADAT | KMT2A 1451/4885ATM 1339/4885MEN1 1857/4885 |
| US-20160237067-A1 | SUBSTITUTED PHENYLALANINE DERIVATIVES | PAH, PEPD, AADAT | KMT2A 1451/4885ATM 1339/4885MEN1 1857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.